Newsroom

UK MasterChef winner Tim Anderson experiments with 3D printed pasta

The winner of MasterChef UK series 7, Tim Anderson, experimented with 3D printed pasta from BluRhapsody, a collaboration between Italian pasta makers Barilla and TNO. The results were satisfactory. Kjeld van Bommel, senior consultant 3D Food and Pharma Printing at TNO, explains how the triple collaboration took shape.

Our latest developments

220 resultaten, getoond 6 t/m 10

Handbook to help with detection

Informatietype:
News
16 November 2022

Everyone can live a contribution to detection. But how can police and citizen (organisations) work together to ensure our safety and justice? The new TNO handbook 'First Aid for Investigation - Handbook for Citizen Detectives' offers help.

TNO helps accelerate drug development through insight

Informatietype:
Insight
14 November 2022

To find the most effective interventions for complex metabolic diseases, we must first understand the dynamics of disease onset and progression. Only then can key targets and optimal therapeutic windows for more effective treatment be defined. We spoke with Anita van den Hoek, Research Scientist for TNO Metabolic Health, about how TNO helps pharmaceutical companies accelerate drug development through better understanding of disease pathways.

Climate goals achievable with strategic approach

Informatietype:
News
14 November 2022

Both globally and in the Netherlands, we are lagging the Paris climate targets. Meeting the climate targets is urgent, but possible. TNO advocates an integrated approach and demonstrates how we can speed up the process towards climate neutrality.

TNO proves method for effective pediatric drug development

Informatietype:
Insight
14 November 2022

Safe and effective drug dosing for young children come with their own challenges. Up to the age of 18, a child’s metabolism can change significantly. And in the first two years of life, those ontogenic differences can be rapid and dramatic. TNO published its findings from the first drug disposition (mass balance/metabolite profiling) study to conclusively prove that microtracing with accelerator mass spectrometry (AMS) is an effective way to collect clinical data in these young patients. This AMS technology can also be the key to building up more data on drug interventions in pregnant and lactating mothers.

TNO's view of 2030: 50% reduction in lifestyle-related diseases

Informatietype:
Insight
14 November 2022

We look ahead to 2030 and find out, among other things, how we can offer people a healthy environment and with a healthier lifestyle.